TIDMOXB

RNS Number : 9950X

Oxford Biomedica PLC

12 May 2016

Oxford BioMedica Board Change

Oxford, UK - 12 May 2016: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE:OXB), a leading gene and cell therapy group, today announces that Dr Paul Blake will leave the Group when his current contract expires at the end of August 2016. Dr Blake was appointed to Oxford BioMedica's Board as a non-executive Director in January 2010 and subsequently he became Chief Development Officer in September 2014.

John Dawson, Chief Executive Officer of Oxford BioMedica, said: "Paul has made a significant contribution to Oxford BioMedica in both his non-executive and executive capacities. I thank Paul for his contribution to the development and continued success of Oxford BioMedica and wish him the best for his future."

-Ends-

 
 For further information, 
  please contact: 
  Oxford BioMedica plc:                     Tel: +44 (0)1865 
   John Dawson, Chief Executive              783 000 
   Officer 
   Tim Watts, Chief Financial 
   Officer 
  Financial and corporate communications    Tel: +44 (0)20 3709 
   enquiries:                                5700 
   Consilium Strategic Communications 
   Mary-Jane Elliott/Matthew 
   Neal/Chris Welsh/Laura Thornton

Notes for editors

About Oxford BioMedica(R)

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector(R) ) through which the Group develops in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 230 people. Further information is available at www.oxfordbiomedica.co.uk.

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOAEANSFFFEKEFF

(END) Dow Jones Newswires

May 12, 2016 02:00 ET (06:00 GMT)

Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Oxford Biomedica Charts.
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Oxford Biomedica Charts.